October 18, 2018
Daiichi Sankyo said on October 17 that it has filed a new drug application for its investigational FLT3 inhibitor quizartinib for the treatment of acute myeloid leukemia (AML) in Japan. The drug was filed for the indication of relapsed/refractory FLT3-ITD...read more